secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acer Therapeutics Inc. (—)
CIK:        0001069308
Form:       8-K
Filed at:   2023-11-20T23:59:59+00:00
Accession:  0001193125-23-280679
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 3.03, 3.01, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acer Therapeutics acquired by Zevra in all-stock merger; shareholders receive 0.1210 ZVRA shares + CVR
--------------------------------------------------------------------------------

- Merger completed on Nov 17, 2023; Acer becomes wholly-owned subsidiary of Zevra.
- Each ACER share converted into 0.1210 Zevra shares and one contingent value right (CVR).
- All Acer directors and executive officers (CEO Chris Schelling, CFO Harry Palmin) resigned; R. LaDuane Clifton and Joshua Schafer appointed directors.
- Acer's common stock now trades on OTC Pink; Nasdaq delisting expected via Form 25-NSE on Nov 20.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/d608859d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-280679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer